ArticleHaematologica2015

GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.

Leo Rasche et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.